‘I was blown away by the success of our first AI-assisted scientific review pilot,’ the FDA’s commissioner said.
The Food and Drug Administration (FDA) is planning to roll out artificial intelligence across the agency following a successful pilot program.
FDA Commissioner Dr. Marty Makary has directed all FDA centers to immediately start using artificial intelligence (AI) and fully integrate it by the end of June, the FDA said in a May 8 statement.
By June 30, all centers will use what the agency described as a “common, secure generative AI system integrated with FDA’s internal data platforms.”
“I was blown away by the success of our first AI-assisted scientific review pilot,“ Makary said in a statement. ”We need to value our scientists’ time and reduce the amount of non-productive busywork that has historically consumed much of the review process. The agency-wide deployment of these capabilities holds tremendous promise in accelerating the review time for new therapies.”
AI refers to computer systems that can carry out complex tasks typically performed by humans.
“AI can be generally described as a branch of computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making predictions,” FDA officials said in 2023.
Makary said on Thursday that past years have featured discussions on utilizing AI and that it’s time to start using it to save time, with some tasks that once took days now taking mere minutes.
“We at the FDA now have to ask big questions that we’ve never asked before. Why does it take over 10 years for a new drug to come to market? Why are we not modernized with AI and other things? We’ve just completed our first AI-assisted scientific review for a product and that’s just the beginning,” he said earlier in the week on social media platform X.
The rollout across the FDA is being coordinated by Jeremy Walsh, Booz Allen Hamilton’s former chief technologist, who was recently appointed as the agency’s chief AI officer, and Sridhar Mantha, who previously led the Office of Business Informatics at the FDA’s Center for Drug Evaluation and Research.
